ArticleCureus2026
Change of Cervical Cancer Stage at Diagnosis After the COVID-19 Pandemic.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Cervical cancer stage determines prognosis. Screening programs aim to detect cancer early, but the COVID-19 pandemic reduced cervical screening in Mexico by 79%. Our objective was to evaluate changes in the clinical stage at diagnosis, histologic type, time from screening to treatment, and time from diagnosis to treatment of patients with cervical cancer diagnosed before (2019), and during the pandemic (2020-2023). Methods Retrospective secondary data analysis of all newly diagnosed cervical cancer cases at a reference center from 2019 to 2023. Stages at diagnosis before, during, and after the COVID-19 pandemic were compared using the Chi-squared test, time from diagnosis to treatment was tested by the Mann-Whitney U Test. Results Compared to the pre-pandemic period, there was a significant change in the number of patients with cervical cancer during the pandemic period: -19.48% in 2020, followed by a maximum increase of +36% in 2022. Early-stage cervical cancer cases changed by -16.3%, -44.3%, -11.8%, and +6.4% during 2020-2023; locally advanced stages changed by -7.4%, +6.5%, +10%, and -6.4%; and metastatic cases by +94.4%, +58.2%, +36.6%, and +48.4%. Epidermoid cases decreased by -15%, -17%, -11%, and -4%; and adenocarcinoma increased by +72%, +78%, +52%, and +20% in the studied period. Time from screening to treatment increased by 2021 but returned to pre-pandemic lapse in 2023. Conclusion Early-stage cervical cancer decreased during the COVID-19 pandemic, while metastatic stages increased significantly, along with a significant change in histological types, time from screening to diagnosis increased since the COVID-19 pandemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.